Lung Cancer Clinical Trials in Raleigh, NC

Lung Cancer Clinical Trials in Raleigh, NC

View the best 10 lung cancer medical studies in Raleigh, North Carolina. Access promising new therapies by applying to a Raleigh-based Lung Cancer clinical trial.

Trials in Raleigh, North Carolina

Here are the top 10 medical studies for lung cancer in Raleigh, North Carolina

Image of Duke Cancer Institute in Raleigh, United States.

C-TIL051

CAR T-cell Therapy

Recruiting1 awardPhase 1
This trial tests C-TIL051 with anti-PD1 therapy for people with refractory non-small cell lung cancer. It assesses safety & ability to tolerate treatment, & response of the cancer. Participants provide a tumor sample & receive chemo & C-TIL051 & anti-PD1.
Image of Alabama Oncology Bruno Cancer Center ( Site 0001) in Birmingham, United States.

Carboplatin +3 More

Chemotherapy

Recruiting1 awardPhase 3
This trial will compare two treatments for people with squamous non-small cell lung cancer. One treatment will be pembrolizumab plus maintenance olaparib, and the other will be pembrolizumab plus maintenance olaparib placebo. The study's two primary hypotheses are that pembrolizumab plus maintenance olaparib is superior to pembrolizumab plus maintenance olaparib placebo with respect to progression-free survival and overall survival.
Image of Millennium Research & Clinical Development in Houston, United States.

Ifinatamab Deruxtecan (I-DXd)

Antibody-Drug Conjugate

Recruiting1 awardPhase 2
This trial tests a new drug, ifinatamab deruxtecan (I-DXd), on patients with a specific type of lung cancer who have not responded to other treatments. The drug aims to target and kill cancer cells.
Image of I.H.S Health, LLC in Kissimmee, United States.

Treatment

Verified
Recruiting1 award4 criteria
This trial is testing a blood test to see if it can detect lung cancer early in high-risk individuals. Blood samples will be collected from participants who are getting a routine CT scan for lung cancer screening.
Image of Research Site in Phoenix, United States.

Carboplatin +4 More

Chemotherapy

Recruiting1 awardPhase 3
This trial is testing a new cancer treatment combining a drug called durvalumab with chemotherapy. The study will compare how well the new treatment works compared to chemotherapy alone.
Image of Duke University Medical Center in Durham, United States.

GT103

CAR T-cell Therapy

Recruiting1 awardPhase 1
This trial is testing a new cancer drug to see what dose is safe and effective.
Image of UCSF Helen Diller Family Comprehensive Cancer Center in San Francisco, United States.

9-ING-41

GSK-3β inhibitor

Recruiting1 awardPhase 2
This trial is testing a new drug to see if it is safe and effective in treating cancer. The drug is designed to target a protein called GSK-3β, which is found in many different types of cancer cells.
Image of MD Anderson Cancer Center in Houston, United States.

NX-1607

Chemotherapy

Recruiting1 awardPhase 1
This trial is testing NX-1607, a new experimental drug, in adults with advanced cancers that don't respond to standard treatments. The goal is to see if NX-1607 can safely stop or reduce cancer growth, either by itself or with another drug called paclitaxel. Paclitaxel is a widely used anti-cancer drug for treating various types of solid malignant tumors including breast, ovarian, and lung cancers.
Image of Research Site in Tucson, United States.

Durvalumab

Recruiting1 awardPhase 3
This trial is testing whether Durvalumab alone or with Tremelimumab can help patients with a specific type of lung cancer who have already had initial treatment. The drugs aim to boost the immune system to fight off any remaining cancer cells. Durvalumab and Tremelimumab are being studied together for their potential to improve cancer treatment outcomes.
Image of University of California, San Francisco in San Francisco, United States.

Gavo-cel (TC-210)

CAR T-cell Therapy

Recruiting2 awardsPhase 1 & 2
This trial is testing a new cell therapy that consists of T cells that have been genetically engineered to express a single-domain antibody that recognizes human Mesothelin. The T cells are fused to the CD3-epsilon subunit, which is incorporated into the endogenous T cell receptor (TCR) complex. The aim of the trial is to establish the recommended Phase 2 dose and to evaluate the efficacy of the therapy in patients with advanced mesothelin-expressing cancers.

Phase 3 Trials

Trials With No Placebo

Frequently Asked Questions

Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.